EGFR (epidermal growth factor receptor) is overexpressed in a variety of human cancers (including squamous cell carcinoma of head and neck, colon cancer, and some breast cancers) and therefore is regarded as an ideal target for cancer therapy or imaging purposes. In the current study, we produced a scFv-based near-infrared probe (called cet.Hum.scFv-IRDye-800CW) and evaluated its ability in recognizing and imaging of EGFR-overexpressing tumors in a mouse model. Like the molecular probe consisting of its parental antibody (cetuximab, an FDA-approved monoclonal antibody) and IRD800CW, cet.Hum.scFv-IRDye-800CW was able to recognize EGFR-overexpressing tumors in mice. cet.Hum.scFv-IRDye-800CW was found to be superior to the cetuximab-based probe in imaging of mouse tumors. The tumor-to-background ratio and blood clearance rate were higher when cet.Hum.scFv-IRDye-800CW was used as an imaging probe.

中文翻译：

---

使用 scFv-IRDye800CW 和西妥昔单抗-IRDye800CW 对小鼠异种移植模型中 EGFR 过表达肿瘤进行近红外荧光成像

EGFR（表皮生长因子受体）在多种人类癌症（包括头颈部鳞状细胞癌、结肠癌和一些乳腺癌）中过度表达，因此被认为是癌症治疗或成像目的的理想靶标。在目前的研究中，我们生产了一种基于 scFv 的近红外探针（称为 cet.Hum.scFv-IRDye-800CW），并评估了它在小鼠模型中识别和成像 EGFR 过表达肿瘤的能力。与由其亲本抗体（西妥昔单抗，FDA 批准的单克隆抗体）和 IRD800CW 组成的分子探针一样，cet.Hum.scFv-IRDye-800CW 能够识别小鼠中过度表达 EGFR 的肿瘤。发现 cet.Hum.scFv-IRDye-800CW 在小鼠肿瘤成像方面优于基于西妥昔单抗的探针。cet.Hum时肿瘤-背景比和血液清除率较高。